Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy.
Osteosarcoma is the most common primary bone tumor in childhood and adolescence. The use of combination chemotherapy and surgery enables long-term survival in approximately 60-70% of cases. However, the necessity for surgery, the poor prognosis of patients with metastatic or recurrent disease (long-term survival in only about 20% of cases), and the lack of establishment of second-line chemotherapy suggest that improvements in chemotherapy are desperately needed. Currently, in an effort to extend the protocol with the chemotherapy drugs that already exist, high-dose chemotherapy with/without autologous peripheral blood stem cell transplantation, and tumor-targeted drug delivery systems are under investigation. Future drug developments will no doubt lie in the direction of immunotherapy and anti-angiogenic therapy, as well as the use of cytotoxic drugs. Identifying the genes and signal transduction pathways responsible for the development of osteosarcoma or for the occurrence of malignancy in cases of osteosarcoma will undoubtedly lead to the identification of pathway-specific agents, or possible gene therapy. Furthermore, as increased light is shed on the character of osetoblastic differentiation in osteosarcoma, this will certainly give rise to new treatments utilizing differentiation therapy. This article reviews the current status and perspectives regarding the treatment of osteosarcoma in terms of chemotherapy.
Sakamoto
Akio
A
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Higashi-ku, Maidashi, Fukuoka, 812-8582, Japan. akio@med.kyushu-u.ac.jp
Iwamoto
Yukihide
Y
D000293:Adolescent; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D003131:Combined Modality Therapy; D015195:Drug Design; D004358:Drug Therapy / Q000639:trends; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology
Curr Opin Rheumatol. 2005 Jan;17(1):79-85
15604909
Clin Orthop Relat Res. 2007 Jan;454:237-46
17075380
Eur J Cancer. 2005 Sep;41(14):2184-95
16140527
Mol Cancer Ther. 2005 Apr;4(4):625-31
15827336
Mol Ther. 2005 Feb;11(2):311-9
15668143
Carcinogenesis. 1993 May;14(5):925-8
8099316
Cancer. 1976 Jan;37(1):1-11
1082364
J Clin Oncol. 1992 Jan;10(1):5-15
1370176
Am J Hum Genet. 1986 Jan;38(1):59-66
3004203
Am J Clin Pathol. 2006 Apr;125(4):555-81
16627266
Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85
16831079
Cancer Res. 2005 Mar 1;65(5):1748-54
15753370
Cancer Chemother Pharmacol. 1989;24 Suppl 1:S28-9
2758568
Cancer Res. 1993 Nov 15;53(22):5535-41
8221695
Int J Oncol. 2006 Jan;28(1):261-9
16328004
Cancer Treat Rev. 2006 Oct;32(6):423-36
16860938
Pediatr Blood Cancer. 2004 Jan;42(1):46-51
14752794
Cancer Res. 2005 May 1;65(9):3868-76
15867386
Bone Marrow Transplant. 2001 May;27(9):933-7
11436103
Int J Epidemiol. 1997 Apr;26(2):272-8
9169161
J Clin Oncol. 2002 Feb 1;20(3):776-90
11821461
Curr Cancer Drug Targets. 2006 Mar;6(2):123-33
16529542
Pediatr Hematol Oncol. 1992 Apr-Jun;9(2):125-37
1524989
Cancer. 2005 Nov 15;104(10):2214-21
16206297
Cancer Genet Cytogenet. 1997 Jan;93(1):100-6
9062585
Oncology. 2003;65 Suppl 2:99-104
14586158
Clin Orthop Relat Res. 1973 Nov-Dec;(97):64-8
4521231
J Fla Med Assoc. 1979 Jan;66(1):28-30
283195
J Clin Oncol. 2005 Mar 20;23(9):2004-11
15774791
Clin Orthop Relat Res. 1991 Sep;(270):237-46
1679382
Cancer Res. 2005 Mar 15;65(6):2406-11
15781656
J Natl Cancer Inst. 2003 May 7;95(9):669-74
12734318
Bone. 2001 Jan;28(1):104-7
11165949
Int Immunopharmacol. 2002 Jan;2(1):25-38
11789667
Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90
15717738
Cancer Detect Prev. 1999;23(2):129-36
10101594
Expert Rev Anticancer Ther. 2007 Feb;7(2):169-81
17288528
Cancer. 1981 Oct 1;48(7):1569-81
6945143
J Clin Oncol. 1994 Dec;12(12):2614-20
7989936
Cancer. 1982 Mar 15;49(6):1221-30
6174200
Pediatr Blood Cancer. 2004 Nov;43(6):692-7
15390283
Cancer. 1992 Feb 1;69(3):698-708
1730120
Clin Orthop Relat Res. 2002 Apr;(397):40-52
11953594
Pediatr Blood Cancer. 2004 May;42(5):410-5
15049011
Curr Oncol Rep. 2003 Mar;5(2):114-25
12583828
Semin Oncol. 1997 Oct;24(5):561-71
9344323
J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):440-6
12218590
Cancer. 2003 Dec 1;98(11):2447-56
14635080
Am J Vet Res. 2005 May;66(5):885-91
15934617
Proc Natl Acad Sci U S A. 1987 Nov;84(21):7716-9
2823272
Cancer. 1967 Jun;20(6):967-73
5229526
Chemioterapia. 1988 Apr;7(2):133-7
3165057
J Clin Oncol. 1991 Aug;9(8):1357-62
2072139
Cancer. 2005 Dec 1;104(11):2522-9
16270320
J Bone Miner Res. 2000 Sep;15(9):1766-75
10976996
J Clin Oncol. 2002 Apr 15;20(8):2150-6
11956277
J Clin Oncol. 2003 Feb 15;21(4):710-5
12586810
Eur J Cancer. 2003 Mar;39(4):488-94
12751380
Clin Cancer Res. 2002 Nov;8(11):3584-91
12429650
Clin Orthop Relat Res. 2000 Apr;(373):39-50
10810461
Cancer Invest. 2001;19(3):292-315
11338887
J Biol Chem. 1999 Feb 12;274(7):4266-72
9933627
J Chemother. 2002 Apr;14(2):198-206
12017378
Cancer Treat Rep. 1979 May;63(5):739-51
313245
J Clin Oncol. 2002 Jan 15;20(2):426-33
11786570